Cadence Pharmaceuticals is a manufactures of medicines , especially pain management solutions.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. On May 4, 2010 Cadence resubmitted a New Drug Application for its investigational product candidate, OFIRMEVTM (acetaminophen) injection for the treatment of pain and fever in adults and children. The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) action date for OFIRMEV of November 4, 2010.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 23, 2009 | Post-IPO Equity | $86.60M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Versant Ventures | — | Post-IPO Equity |